Pharmaceutical Information |
Drug Name |
Mephenytoin |
Drug ID |
BADD_D01386 |
Description |
Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incidences of blood dyscrasias compared to other anticonvulsants. |
Indications and Usage |
For the treatment of refractory partial epilepsy. |
Marketing Status |
approved; investigational; withdrawn |
ATC Code |
N03AB04 |
DrugBank ID |
DB00532
|
KEGG ID |
D00375
|
MeSH ID |
D008617
|
PubChem ID |
4060
|
TTD Drug ID |
D07RGW
|
NDC Product Code |
Not Available |
UNII |
R420KW629U
|
Synonyms |
Mephenytoin | 5-Ethyl-3-Methyl-5-Phenylhydantoin | 5 Ethyl 3 Methyl 5 Phenylhydantoin | Mefenetoin | Methoin | Methyl Phenetoin | Phenetoin, Methyl | Phenantoin | Mesantoin |
|
Chemical Information |
Molecular Formula |
C12H14N2O2 |
CAS Registry Number |
50-12-4 |
SMILES |
CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2 |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|